Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is a Chinese pharmaceutical firm actively involved in the full spectrum of drug development, from research and development to manufacturing and sales. Its therapeutic focus primarily encompasses key areas such as rheumatism, digestive health, oncology, and gynecology. The company boasts a comprehensive and diverse product portfolio. This includes a wide array of traditional Chinese medicines (TCMs), addressing conditions like gynecological issues, rheumatic and bone pain, urological disorders, detoxification needs, cardiovascular and cerebral health, digestive and respiratory ailments, diabetes, and pediatric concerns. Beyond TCMs, it also develops and markets anti-tumor drugs, both prescription and over-the-counter (OTC) medications, and conventional Western pharmaceuticals. These products are available in multiple dosage forms, including capsules, tablets, injections, and liquid preparations. Established in 1990, the company is headquartered in Tonghua, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI